微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 48.87% | -13.96% | -12.15% | 79/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 55.63% | -4.81% | 0.68% | 62/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 55.25% | -5.02% | -1.24% | 65/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 55.94% | -2.43% | -1.51% | 62/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 56.8% | -2.66% | -2.79% | 58/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 58.44% | -2.39% | 0.46% | 53/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 58.17% | -2.82% | 1.45% | 57/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 57.34% | -7.63% | -1.74% | 61/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 58.35% | -5.07% | -2.53% | 54/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 59.87% | -9.36% | 0.02% | 54/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 59.86% | -12.02% | -3.57% | 55/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 62.08% | -10.56% | 0.99% | 51/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 61.47% | -15.14% | -6.94% | 51/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 66.05% | -4.37% | -2.91% | 46/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 68.03% | -0.1% | -1.98% | 43/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 69.4% | 3.13% | -4.19% | 42/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 72.44% | 15.78% | 4.88% | 36/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 69.07% | 18.37% | 1.42% | 46/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 68.1% | 9.53% | 1.2% | 38/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 67.29% | 8.81% | 7.55% | 43/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 62.57% | 12.69% | 7.24% | 45/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 58.35% | -16.31% | -6.16% | 61/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 62.17% | -15.67% | 0.53% | 49/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 61.84% | -18.36% | 11.38% | 49/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 55.52% | -26.5% | -20.36% | 51/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 69.71% | 2.9% | -5.44% | 38/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 73.72% | 11.79% | -2.67% | 19/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 75.75% | 16.56% | 0.28% | 21/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 75.54% | 10.21% | 11.5% | 16/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 67.75% | 18.1% | 2.72% | 39/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 65.95% | 19.17% | 1.48% | 26/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 64.99% | 26.4% | -5.18% | 28/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 68.54% | 53% | 19.48% | 24/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 57.37% | 54.95% | 3.66% | 50/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 55.34% | 56.88% | 7.64% | 37/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 51.42% | 48.01% | 14.76% | 42/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 44.8% | 73.14% | 21.01% | 44/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 37.02% | 0.95% | 4.95% | 74/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 35.28% | -22.68% | 1.55% | 52/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 34.74% | -31.63% | 34.25% | 62/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 25.88% | -53.89% | -29.45% | 66/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |